BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 18166178)

  • 1. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
    Reh A; Oktem O; Oktay K
    Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian function and childbearing issues in breast cancer survivors.
    Gadducci A; Cosio S; Genazzani AR
    Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
    Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
    Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
    Yasumura T; Oka T; Honjo H; Okada H
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
    Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
    Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
    Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
    Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R
    Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.
    Petrek JA; Naughton MJ; Case LD; Paskett ED; Naftalis EZ; Singletary SE; Sukumvanich P
    J Clin Oncol; 2006 Mar; 24(7):1045-51. PubMed ID: 16476708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
    Peccatori F; Demeestere I
    Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
    [No Abstract]   [Full Text] [Related]  

  • 10. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.
    Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P
    Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
    Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
    J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Breast cancer and fertility: critical review, considerations and perspectives].
    This P
    Bull Cancer; 2008 Jan; 95(1):17-25. PubMed ID: 18230566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
    Fornier MN; Modi S; Panageas KS; Norton L; Hudis C
    Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
    Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
    World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring the impact of chemotherapy on fertility in women with breast cancer.
    Oktay K; Oktem O; Reh A; Vahdat L
    J Clin Oncol; 2006 Aug; 24(24):4044-6. PubMed ID: 16921067
    [No Abstract]   [Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
    Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
    Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of chemotherapy to ovary function in ovarian malignancy patients undergoing conservative surgery].
    Sun ZY; Shen K; Lang JH; Huang HF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):431-3. PubMed ID: 12974089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen deficiency and bone loss in women with breast cancer.
    Shapiro CL
    Breast Cancer Res Treat; 2010 Oct; 123(3):815-8. PubMed ID: 20697804
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
    Davis AL; Klitus M; Mintzer DM
    Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.